about
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAPMutations in GNA11 in uveal melanomaFrequent somatic mutations of GNAQ in uveal melanoma and blue naeviMelanoma: oncogenic drivers and the immune systemUveal melanoma cells utilize a novel route for transendothelial migrationBRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.The genetics of uveal melanoma: current insightsConnecting molecular pathways to hereditary cancer risk syndromesOcular prostheses in the last century: a retrospective analysis of 8018 patientsExtracutaneous melanomas: a primer for the radiologist.Treatment of primary intraocular melanoma.Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasisThe antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.Systematic genomic and translational efficiency studies of uveal melanoma.Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study.Melanoma: clinical features and genomic insights.Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progressionThe genetics of uveal melanoma: an emerging framework for targeted therapyIdentification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma.High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R.A pilot study of bevacizumab and interferon-α2b in ocular melanoma.Rare presentations of primary melanoma and special populations: a systematic review.Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?Identify the signature genes for diagnose of uveal melanoma by weight gene co-expression network analysis.Molecular prognostic testing and individualized patient care in uveal melanoma.Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaReduced expression of autotaxin predicts survival in uveal melanoma.Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility.Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case reportEstablishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.Differential expression of TYRP1 in adult human retinal pigment epithelium and uveal melanoma cells.Prognostic factors of choroidal melanoma in Slovenia, 1986-2008.Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanomaTERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQ(Q209L)-driven melanoma.
P2860
Q24298571-9DB8055B-BB86-4C8C-930B-F661D72754A7Q24625723-298CA5C6-009D-4E33-AF74-1F6E39CB29A7Q24646052-A426708E-514E-4C11-8AE7-08A7FDDD74FCQ26775598-0FD0CCC9-70D1-44B7-AB56-A11220117112Q27319660-071F6484-D2B6-45B8-ACE2-814787FA9240Q27853217-616DB72B-4621-4163-B7E4-C3C7F429BBBBQ28073150-D46A4D66-F435-4B9F-80BF-3745FCABC9C3Q28291516-6F72A4F8-D18C-47D2-9D6C-0D3A93B62E38Q28385575-CB317013-2983-4977-9A90-1E6438639F53Q30397680-B0BC6851-93A9-4C7D-B581-AE45C9130D7EQ33239855-C642D195-286F-4788-BF9D-7C2901CDFCFAQ33640617-100D2F84-A6D2-4A84-9114-7912F5DBF22AQ33703068-07C59E58-EE78-44E5-9679-8126EF20976EQ33778295-0347C1C1-A3FD-47C7-A559-297F0E431933Q33805302-42D20F92-20F3-424B-9AD3-3DB219291771Q34083191-5ABF0729-143A-4869-84CE-C0D29986F270Q34135637-A0FC3BC5-736F-43B5-9FF5-9C74D780083AQ34249080-BD2B819B-0BFF-4169-BE10-BF57ED38F15BQ34272199-BEC1D372-3731-44B3-8411-8C2D225F87EAQ34287626-B4FCE3D4-B007-4119-8515-F12965DB1820Q34398217-AB523B29-B010-4FE5-A3F6-1D62F6985A6DQ34414476-1A5282E7-C897-420B-A8F8-6CC65EC06D39Q34745869-C5537891-FA60-4A4F-98A3-D941B030DC24Q34961777-F375742F-0D21-4A35-A829-1E930F24FECAQ35147046-9A80721C-14CA-44C8-9C39-CC4EB20B6642Q35324807-C6A3B3B0-7EC2-4837-B819-AAE5053CBFFBQ35550027-FDE81ACF-4D69-4063-A202-5CA4F7F56501Q35750425-00BECE64-8964-420F-9B4A-B434AE4F45BDQ35915107-6AA81787-2EE3-4EDE-9D60-F6C1731BDAFBQ35928569-06D8BBD7-63C3-4883-9CAE-95F0C7EF5776Q36025959-E475980B-3CC7-4909-85B7-37EC20960C20Q36054784-F40BBE63-ED76-426A-B5A8-8AAE21B21CA0Q36100681-59CDCBA5-6CD9-482A-AF43-B10ABC17D019Q36138969-8C24A0DB-D2B9-4541-9C18-440334B2A273Q36468749-4EA71036-0737-405C-9DBC-4358A94FF7EEQ36742234-27AEDD3C-625C-4C92-9938-85851B422E0AQ36779868-136BAE00-023D-4396-8D12-202B74DBB29EQ36804878-18C0C326-6883-444D-8DFF-54DA30F7B7E7Q37040678-DF340304-4789-43E0-A577-3801B34ADAFFQ37096232-4D77A28D-2BF3-4BAD-823C-A70104D61302
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Uveal melanoma: epidemiologic aspects.
@ast
Uveal melanoma: epidemiologic aspects.
@en
Uveal melanoma: epidemiologic aspects.
@nl
type
label
Uveal melanoma: epidemiologic aspects.
@ast
Uveal melanoma: epidemiologic aspects.
@en
Uveal melanoma: epidemiologic aspects.
@nl
prefLabel
Uveal melanoma: epidemiologic aspects.
@ast
Uveal melanoma: epidemiologic aspects.
@en
Uveal melanoma: epidemiologic aspects.
@nl
P2093
P1476
Uveal melanoma: epidemiologic aspects.
@en
P2093
Arun D Singh
Louise Bergman
Stefan Seregard
P304
75-84, viii
P356
10.1016/J.OHC.2004.07.002
P577
2005-03-01T00:00:00Z